CA2074188C - Vecteur dote de multiples elements de reponse d'activation de la tat ayant un effet genique - Google Patents

Vecteur dote de multiples elements de reponse d'activation de la tat ayant un effet genique Download PDF

Info

Publication number
CA2074188C
CA2074188C CA002074188A CA2074188A CA2074188C CA 2074188 C CA2074188 C CA 2074188C CA 002074188 A CA002074188 A CA 002074188A CA 2074188 A CA2074188 A CA 2074188A CA 2074188 C CA2074188 C CA 2074188C
Authority
CA
Canada
Prior art keywords
dna construct
hiv
construct according
ltr
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002074188A
Other languages
English (en)
Other versions
CA2074188A1 (fr
Inventor
Julianna Lisziewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Commerce
Original Assignee
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Commerce filed Critical US Department of Commerce
Publication of CA2074188A1 publication Critical patent/CA2074188A1/fr
Application granted granted Critical
Publication of CA2074188C publication Critical patent/CA2074188C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002074188A 1990-01-18 1991-01-16 Vecteur dote de multiples elements de reponse d'activation de la tat ayant un effet genique Expired - Fee Related CA2074188C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46740790A 1990-01-18 1990-01-18
US467,407 1990-01-18
US59629990A 1990-10-15 1990-10-15
US596,299 1990-10-15
PCT/US1991/000175 WO1991010453A1 (fr) 1990-01-18 1991-01-16 Vecteur a elements multiples de reponse de cibles affectant l'expression de genes

Publications (2)

Publication Number Publication Date
CA2074188A1 CA2074188A1 (fr) 1991-07-19
CA2074188C true CA2074188C (fr) 2004-05-11

Family

ID=27042041

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002074188A Expired - Fee Related CA2074188C (fr) 1990-01-18 1991-01-16 Vecteur dote de multiples elements de reponse d'activation de la tat ayant un effet genique

Country Status (6)

Country Link
EP (1) EP0511285A4 (fr)
JP (1) JP2746480B2 (fr)
KR (1) KR0148782B1 (fr)
AU (1) AU642959B2 (fr)
CA (1) CA2074188C (fr)
WO (1) WO1991010453A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2752788B2 (ja) * 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5871958A (en) * 1989-05-25 1999-02-16 Duke University Mutant rev genes encoding transdominant repressors of HIV replication
US6251675B1 (en) 1989-05-25 2001-06-26 Duke University Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication
US6245560B1 (en) 1990-01-18 2001-06-12 The United States Of America As Represented By The Department Of Health And Human Services Vector with multiple target response elements affecting gene expression
GB9125623D0 (en) * 1991-12-02 1992-01-29 Dynal As Cell modification
GB9206874D0 (en) * 1992-03-30 1992-05-13 Connaught Lab Generation of improved inducible mammalian expression vectors
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) * 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5686599A (en) * 1992-05-14 1997-11-11 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5654398A (en) * 1993-06-03 1997-08-05 The Regents Of The University Of California Compositions and methods for inhibiting replication of human immunodeficiency virus-1
GB9319772D0 (en) * 1993-09-24 1993-11-10 Therexsys Ltd Therapeutic agent
US5877018A (en) * 1994-10-20 1999-03-02 Connaught Laboratories Limited Synthetic eukaryotic promoters containing two inducible elements
NZ315890A (en) * 1995-08-25 1998-10-28 Univ California Chimeric antiviral agents which incorporate rev binding nucleic acids
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
EP1555317B1 (fr) * 1998-03-20 2011-09-28 Commonwealth Scientific And Industrial Research Organisation Genes synthetiques et constructions genetiques comprenant ces genes
AU9196798A (en) * 1998-05-04 1999-11-23 Julianna Lisziewicz Chimeric decoy rnas having synergistic anti-hiv activity
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO2006088740A2 (fr) 2005-02-15 2006-08-24 Thymon, L.L.C. Methodes et compositions permettant d'alterer la multiplication de vih-1
IT1397569B1 (it) 2009-12-10 2013-01-16 Icgeb Peptidi e loro derivati che inibiscono il rilascio extracellulare della proteina tat di hiv-1 e la replicazione di hiv-1.

Also Published As

Publication number Publication date
WO1991010453A1 (fr) 1991-07-25
KR0148782B1 (ko) 1998-08-17
KR920703118A (ko) 1992-12-17
EP0511285A4 (en) 1993-05-26
JP2746480B2 (ja) 1998-05-06
JPH05504255A (ja) 1993-07-08
CA2074188A1 (fr) 1991-07-19
AU642959B2 (en) 1993-11-04
AU7074091A (en) 1991-08-05
EP0511285A1 (fr) 1992-11-04

Similar Documents

Publication Publication Date Title
CA2074188C (fr) Vecteur dote de multiples elements de reponse d'activation de la tat ayant un effet genique
Fisher et al. The trans-activator gene of HTLV-III is essential for virus replication
Garcia et al. Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation.
US6107062A (en) Antisense viruses and antisense-ribozyme viruses
Emerman et al. The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1.
Rosen et al. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat
Pearson et al. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.
BouHamdan et al. Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme
Luciw et al. Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication.
Lee et al. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain
Marciniak et al. HIV-1 Tat protein trans-activates transcription in vitro
Newstein et al. Human chromosome 12 encodes a species-specific factor which increases human immunodeficiency virus type 1 tat-mediated trans activation in rodent cells
WO1990013641A1 (fr) Cellules eucaryotes transformees de maniere stable comprenant un adn etranger susceptible d'etre transcrit sous la direction d'un promoteur pol iii
Fenrick et al. Functional analysis of the Tat trans activator of human immunodeficiency virus type 2
Arrigo et al. cis-Acting regulatory elements within gag genes of avian retroviruses
Carvalho et al. Mutational analysis of the equine infectious anemia virus Tat-responsive element
Yang et al. Human T cell transcription factor GATA-3 stimulates HIV-1 expression
Berberich et al. Mutations in the regions of the Rous sarcoma virus 3'splice sites: implications for regulation of alternative splicing
US5985661A (en) Anti-HIV ribozymes
Pelley et al. Proviral-activated c-erbB is leukemogenic but not sarcomagenic: characterization of a replication-competent retrovirus containing the activated c-erbB
US6245560B1 (en) Vector with multiple target response elements affecting gene expression
LARSSON et al. A Novel Ribozyme Target Site Located in the HIV-1NefOpen Reading Frame
Lee et al. Multiple positive and negative cis-acting elements that mediate transactivation by bel1 in the long terminal repeat of human foamy virus
WO1994016060A1 (fr) Mutants de vih destines a la suppression des infections par vih
Shukla et al. Human immunodeficiency virus type 1 Rev-responsive element RNA binds to host cell-specific proteins

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed